{"pmid":32374032,"title":"Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors.","text":["Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors.","We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].","Aliment Pharmacol Ther","Garg, Mayur","Royce, Simon G","Lubel, John S","32374032"],"abstract":["We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2]."],"journal":"Aliment Pharmacol Ther","authors":["Garg, Mayur","Royce, Simon G","Lubel, John S"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374032","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/apt.15814","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496348192769,"score":9.490897,"similar":[{"pmid":32359205,"title":"2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases.","text":["2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases.","BACKGROUND: Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS-CoV-2) disease (COVID-19) are lacking. AIM: To report the clinical characteristics, including gastrointestinal symptoms, of COVID-19 in IBD patients, and to assess the risk of COVID-19 in IBD. METHODS: This case series included consecutive IBD patients with laboratory-confirmed COVID-19. Age-adjusted cumulative incidences were compared with the general population in the Madrid region. RESULTS: Through April 8, 12 patients of 1918 IBD patients were diagnosed of COVID-19. The average age was 52 years, 75% of the patients were female, and 58.3% had Crohn's disease. Seven patients (58%) were on maintenance treatment with immunomodulators/biologics, of these 4 with combined therapy (33%). Eight patients (66%) required hospitalization (1 intensive care unit admission, and 2 deaths), and 4 patients were isolated at home. Nine patients had diarrhoea ranging between 4-10 loose stools per day (mean 5.4, SD 1.6). In 5 patients (42%) diarrhoea was a presenting symptom. In 2 patients, diarrhoea was the only symptom at debut. Cumulative incidence of COVID-19 was 6.1 per 1000 IBD patients. IBD patients had a lower adjusted incidence ratio of COVID-19 (OR 0.74, 95% CI 0.70-0.77; p<0.001), and a similar associated mortality ratio (OR 0.95, 95% CI: 0.84-1.06; p=0.36), compared with the general population. CONCLUSIONS: IBD patients do not have an increased risk of COVID-19 and associated mortality compared with the general population. In many IBD patients diarrhoea was a presenting symptom, and sometimes, was the only symptom at onset of COVID-19.","Aliment Pharmacol Ther","Taxonera, Carlos","Sagastagoitia, Inigo","Alba, Cristina","Manas, Norberto","Olivares, David","Rey, Enrique","32359205"],"abstract":["BACKGROUND: Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS-CoV-2) disease (COVID-19) are lacking. AIM: To report the clinical characteristics, including gastrointestinal symptoms, of COVID-19 in IBD patients, and to assess the risk of COVID-19 in IBD. METHODS: This case series included consecutive IBD patients with laboratory-confirmed COVID-19. Age-adjusted cumulative incidences were compared with the general population in the Madrid region. RESULTS: Through April 8, 12 patients of 1918 IBD patients were diagnosed of COVID-19. The average age was 52 years, 75% of the patients were female, and 58.3% had Crohn's disease. Seven patients (58%) were on maintenance treatment with immunomodulators/biologics, of these 4 with combined therapy (33%). Eight patients (66%) required hospitalization (1 intensive care unit admission, and 2 deaths), and 4 patients were isolated at home. Nine patients had diarrhoea ranging between 4-10 loose stools per day (mean 5.4, SD 1.6). In 5 patients (42%) diarrhoea was a presenting symptom. In 2 patients, diarrhoea was the only symptom at debut. Cumulative incidence of COVID-19 was 6.1 per 1000 IBD patients. IBD patients had a lower adjusted incidence ratio of COVID-19 (OR 0.74, 95% CI 0.70-0.77; p<0.001), and a similar associated mortality ratio (OR 0.95, 95% CI: 0.84-1.06; p=0.36), compared with the general population. CONCLUSIONS: IBD patients do not have an increased risk of COVID-19 and associated mortality compared with the general population. In many IBD patients diarrhoea was a presenting symptom, and sometimes, was the only symptom at onset of COVID-19."],"journal":"Aliment Pharmacol Ther","authors":["Taxonera, Carlos","Sagastagoitia, Inigo","Alba, Cristina","Manas, Norberto","Olivares, David","Rey, Enrique"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359205","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/apt.15804","keywords":["covid-19","sars-cov-2","diarrhoea","inflammatory bowel disease"],"locations":["Madrid"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495306956801,"score":184.01538},{"pmid":32333601,"pmcid":"PMC7188157","title":"Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD.","text":["Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD.","BACKGROUND: Patients with inflammatory bowel disease (IBD) have intestinal inflammation and are treated with immune-modulating medications. In the face of the coronavirus disease-19 pandemic, we do not know whether patients with IBD will be more susceptible to infection or disease. We hypothesized that the viral entry molecules angiotensin I converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) are expressed in the intestine. We further hypothesized that their expression could be affected by inflammation or medication usage. METHODS: We examined the expression of Ace2 and Tmprss2 by quantitative polymerase chain reacion in animal models of IBD. Publicly available data from organoids and mucosal biopsies from patients with IBD were examined for expression of ACE2 and TMPRSS2. We conducted RNA sequencing for CD11b-enriched cells and peripheral and lamina propria T-cells from well-annotated patient samples. RESULTS: The molecules ACE2 and TMPRSS2 were abundantly expressed in the ileum and colon and had high expression in intestinal epithelial cells. In animal models, inflammation led to downregulation of epithelial Ace2. Expression of ACE2 and TMPRSS2 was not increased in samples from patients with compared with those of control patients. In CD11b-enriched cells but not T-cells, the level of expression of ACE2 and TMPRSS2 in the mucosa was comparable to other functional mucosal genes and was not affected by inflammation. Anti-tumor necrosis factor drugs, vedolizumab, ustekinumab, and steroids were linked to significantly lower expression of ACE2 in CD11b-enriched cells. CONCLUSIONS: The viral entry molecules ACE2 and TMPRSS2 are expressed in the ileum and colon. Patients with IBD do not have higher expression during inflammation; medical therapy is associated with lower levels of ACE2. These data provide reassurance for patients with IBD.","Inflamm Bowel Dis","Burgueno, Juan F","Reich, Adrian","Hazime, Hajar","Quintero, Maria A","Irina, Fernandez","Fritsch, Julia","Santander, Ana M","Brito, Nivis","Damas, Oriana M","Deshpande, Amar","Kerman, David H","Zhang, Lanyu","Gao, Zhen","Ban, Yuguang","Wang, Lily","Pignac-Kobinger, Judith","Abreu, Maria T","32333601"],"abstract":["BACKGROUND: Patients with inflammatory bowel disease (IBD) have intestinal inflammation and are treated with immune-modulating medications. In the face of the coronavirus disease-19 pandemic, we do not know whether patients with IBD will be more susceptible to infection or disease. We hypothesized that the viral entry molecules angiotensin I converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) are expressed in the intestine. We further hypothesized that their expression could be affected by inflammation or medication usage. METHODS: We examined the expression of Ace2 and Tmprss2 by quantitative polymerase chain reacion in animal models of IBD. Publicly available data from organoids and mucosal biopsies from patients with IBD were examined for expression of ACE2 and TMPRSS2. We conducted RNA sequencing for CD11b-enriched cells and peripheral and lamina propria T-cells from well-annotated patient samples. RESULTS: The molecules ACE2 and TMPRSS2 were abundantly expressed in the ileum and colon and had high expression in intestinal epithelial cells. In animal models, inflammation led to downregulation of epithelial Ace2. Expression of ACE2 and TMPRSS2 was not increased in samples from patients with compared with those of control patients. In CD11b-enriched cells but not T-cells, the level of expression of ACE2 and TMPRSS2 in the mucosa was comparable to other functional mucosal genes and was not affected by inflammation. Anti-tumor necrosis factor drugs, vedolizumab, ustekinumab, and steroids were linked to significantly lower expression of ACE2 in CD11b-enriched cells. CONCLUSIONS: The viral entry molecules ACE2 and TMPRSS2 are expressed in the ileum and colon. Patients with IBD do not have higher expression during inflammation; medical therapy is associated with lower levels of ACE2. These data provide reassurance for patients with IBD."],"journal":"Inflamm Bowel Dis","authors":["Burgueno, Juan F","Reich, Adrian","Hazime, Hajar","Quintero, Maria A","Irina, Fernandez","Fritsch, Julia","Santander, Ana M","Brito, Nivis","Damas, Oriana M","Deshpande, Amar","Kerman, David H","Zhang, Lanyu","Gao, Zhen","Ban, Yuguang","Wang, Lily","Pignac-Kobinger, Judith","Abreu, Maria T"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333601","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1093/ibd/izaa085","keywords":["crohn disease","coronavirus","ulcerative colitis"],"locations":["vedolizumab"],"e_drugs":["Serine","Ustekinumab","Steroids","vedolizumab"],"topics":["Mechanism"],"weight":1,"_version_":1666138494047617024,"score":161.70753},{"pmid":32222988,"pmcid":"PMC7161803","title":"Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission.","text":["Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission.","BACKGROUND: There is little published evidence on the gastrointestinal features of COVID-19. AIMS: To report on the gastrointestinal manifestations and pathological findings of patients with COVID-19, and to discuss the possibility of faecal transmission. METHODS: We have reviewed gastrointestinal features of, and faecal test results in, COVID-19 from case reports and retrospective clinical studies relating to the digestive system published since the outbreak. RESULTS: With an incidence of 3% (1/41)-79% (159/201), gastrointestinal symptoms of COVID-19 included anorexia 39.9% (55/138)-50.2% (101/201), diarrhoea 2% (2/99)-49.5% (146/295), vomiting 3.6% (5/138)-66.7% (4/6), nausea 1% (1/99)-29.4% (59/201), abdominal pain 2.2% (3/138)-6.0% (12/201) and gastrointestinal bleeding 4% (2/52)-13.7% (10/73). Diarrhoea was the most common gastrointestinal symptom in children and adults, with a mean duration of 4.1 +/- 2.5 days, and was observed before and after diagnosis. Vomiting was more prominent in children. About 3.6% (5/138)-15.9% (32/201) of adult and 6.5% (2/31)-66.7% (4/6) of children patients presented vomiting. Adult and children patients can present with digestive symptoms in the absence of respiratory symptoms. The incidence of digestive manifestations was higher in the later than in the early stage of the epidemic, but no differences in digestive symptoms among different regions were found. Among the group of patients with a higher proportion of severe cases, the proportion of gastrointestinal symptoms in severe patients was higher than that in nonsevere patients (anorexia 66.7% vs 30.4%; abdominal pain 8.3% vs 0%); while in the group of patients with a lower severe rate, the proportion with gastrointestinal symptoms was similar in severe and nonsevere cases (nausea and vomiting 6.9% vs 4.6%; diarrhoea 5.8% vs 3.5%). Angiotensin converting enzyme 2 and virus nucleocapsid protein were detected in gastrointestinal epithelial cells, and infectious virus particles were isolated from faeces. Faecal PCR testing was as accurate as respiratory specimen PCR detection. In 36% (5/14)-53% (39/73) faecal PCR became positive, 2-5 days later than sputum PCR positive. Faecal excretion persisted after sputum excretion in 23% (17/73)-82% (54/66) patients for 1-11 days. CONCLUSIONS: Gastrointestinal symptoms are common in patients with COVID-19, and had an increased prevalence in the later stage of the recent epidemic in China. SARS-CoV-2 enters gastrointestinal epithelial cells, and the faeces of COVID-19 patients are potentially infectious.","Aliment Pharmacol Ther","Tian, Yuan","Rong, Long","Nian, Weidong","He, Yan","32222988"],"abstract":["BACKGROUND: There is little published evidence on the gastrointestinal features of COVID-19. AIMS: To report on the gastrointestinal manifestations and pathological findings of patients with COVID-19, and to discuss the possibility of faecal transmission. METHODS: We have reviewed gastrointestinal features of, and faecal test results in, COVID-19 from case reports and retrospective clinical studies relating to the digestive system published since the outbreak. RESULTS: With an incidence of 3% (1/41)-79% (159/201), gastrointestinal symptoms of COVID-19 included anorexia 39.9% (55/138)-50.2% (101/201), diarrhoea 2% (2/99)-49.5% (146/295), vomiting 3.6% (5/138)-66.7% (4/6), nausea 1% (1/99)-29.4% (59/201), abdominal pain 2.2% (3/138)-6.0% (12/201) and gastrointestinal bleeding 4% (2/52)-13.7% (10/73). Diarrhoea was the most common gastrointestinal symptom in children and adults, with a mean duration of 4.1 +/- 2.5 days, and was observed before and after diagnosis. Vomiting was more prominent in children. About 3.6% (5/138)-15.9% (32/201) of adult and 6.5% (2/31)-66.7% (4/6) of children patients presented vomiting. Adult and children patients can present with digestive symptoms in the absence of respiratory symptoms. The incidence of digestive manifestations was higher in the later than in the early stage of the epidemic, but no differences in digestive symptoms among different regions were found. Among the group of patients with a higher proportion of severe cases, the proportion of gastrointestinal symptoms in severe patients was higher than that in nonsevere patients (anorexia 66.7% vs 30.4%; abdominal pain 8.3% vs 0%); while in the group of patients with a lower severe rate, the proportion with gastrointestinal symptoms was similar in severe and nonsevere cases (nausea and vomiting 6.9% vs 4.6%; diarrhoea 5.8% vs 3.5%). Angiotensin converting enzyme 2 and virus nucleocapsid protein were detected in gastrointestinal epithelial cells, and infectious virus particles were isolated from faeces. Faecal PCR testing was as accurate as respiratory specimen PCR detection. In 36% (5/14)-53% (39/73) faecal PCR became positive, 2-5 days later than sputum PCR positive. Faecal excretion persisted after sputum excretion in 23% (17/73)-82% (54/66) patients for 1-11 days. CONCLUSIONS: Gastrointestinal symptoms are common in patients with COVID-19, and had an increased prevalence in the later stage of the recent epidemic in China. SARS-CoV-2 enters gastrointestinal epithelial cells, and the faeces of COVID-19 patients are potentially infectious."],"journal":"Aliment Pharmacol Ther","authors":["Tian, Yuan","Rong, Long","Nian, Weidong","He, Yan"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222988","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1111/apt.15731","link_comment_in":"32281109","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138490228703233,"score":155.00607},{"pmid":32215548,"pmcid":"PMC7184365","title":"Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","text":["Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","Crohn's disease (CD)] and ulcerative colitis (UC), the main inflammatory bowel diseases (IBD) in human beings, are chronic, immune-inflammatory diseases, whose pathogenesis implicates a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant nowadays, as coronavirus disease (Covid-19) has rapidly spread from China to countries where IBD are more prevalent and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the cells and to illustrate the link between such determinants and the intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk to be infected with SARS-CoV-2 and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia.","J Crohns Colitis","Monteleone, Giovanni","Ardizzone, Sandro","32215548"],"abstract":["Crohn's disease (CD)] and ulcerative colitis (UC), the main inflammatory bowel diseases (IBD) in human beings, are chronic, immune-inflammatory diseases, whose pathogenesis implicates a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant nowadays, as coronavirus disease (Covid-19) has rapidly spread from China to countries where IBD are more prevalent and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the cells and to illustrate the link between such determinants and the intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk to be infected with SARS-CoV-2 and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia."],"journal":"J Crohns Colitis","authors":["Monteleone, Giovanni","Ardizzone, Sandro"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32215548","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1093/ecco-jcc/jjaa061","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490514964482,"score":147.14233},{"pmid":32211765,"pmcid":"PMC7184487","title":"Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience.","text":["Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience.","The outbreak of the COVID-19 caused by Coronavirus SARS-CoV2, is rapidly spreading worldwide. This is the first pandemic caused by a Coronavirus in history. More than 150,000 confirmed cases worldwide are reported by the SARS-CoV2, with more than 5,000 COVID-19-related deaths on March 14th, 2020. Fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhoea, confusion, dyspnoea, and bilateral interstitial pneumonia are the common symptoms. No therapies are available, and the only way to contain the virus spread is to regularly and thoroughly clean oneself hands with an alcohol-based hand rub or wash them with soap and water, to maintain at least 1 metre (3 feet) distance from anyone who is coughing or sneezing, to avoid touching eyes, nose and mouth, and to stay home if one feels unwell. No data are available on the risk of COVID-19 and outcomes in inflammatory bowel disease (IBD) patients. Outbreak restrictions can impact on the IBD care. We aim to give a viewpoint on how operationally manage IBD patients ensuring quality of care in the current pandemic era.","J Crohns Colitis","Fiorino, Gionata","Allocca, Mariangela","Furfaro, Federica","Gilardi, Daniela","Zilli, Alessandra","Radice, Simona","Spinelli, Antonino","Danese, Silvio","32211765"],"abstract":["The outbreak of the COVID-19 caused by Coronavirus SARS-CoV2, is rapidly spreading worldwide. This is the first pandemic caused by a Coronavirus in history. More than 150,000 confirmed cases worldwide are reported by the SARS-CoV2, with more than 5,000 COVID-19-related deaths on March 14th, 2020. Fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhoea, confusion, dyspnoea, and bilateral interstitial pneumonia are the common symptoms. No therapies are available, and the only way to contain the virus spread is to regularly and thoroughly clean oneself hands with an alcohol-based hand rub or wash them with soap and water, to maintain at least 1 metre (3 feet) distance from anyone who is coughing or sneezing, to avoid touching eyes, nose and mouth, and to stay home if one feels unwell. No data are available on the risk of COVID-19 and outcomes in inflammatory bowel disease (IBD) patients. Outbreak restrictions can impact on the IBD care. We aim to give a viewpoint on how operationally manage IBD patients ensuring quality of care in the current pandemic era."],"journal":"J Crohns Colitis","authors":["Fiorino, Gionata","Allocca, Mariangela","Furfaro, Federica","Gilardi, Daniela","Zilli, Alessandra","Radice, Simona","Spinelli, Antonino","Danese, Silvio"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32211765","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1093/ecco-jcc/jjaa058","keywords":["covid-19","coronavirus","inflammatory bowel disease","pandemic","quality of care"],"locations":["Humanitas","Milan"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["Alcohols","Water"],"topics":["Prevention"],"weight":1,"_version_":1666138492364652544,"score":132.99194}]}